In her husband's nearly 15 years of living with ALS, columnist Kristin Neva sees pre- and post-diagnosis papers as a bittersweet treasure.

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.

A renowned Israeli TV journalist who lost his ability to speak clearly because of ALS is returning to the air using artificial-intelligence software that recreates his widely recognized gravelly voice ...

Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist to treat ALS failed to meet its primary endpoint of slowing disease progression compared with placebo at week 24.According ...